In recent years, immunotherapy based on immune checkpoint inhibitors has been successful in treating NSCLC, especially in patients with a high tumour mutation burden (TMB), CD8+ tumour cell infiltration, and programmed death-ligand 1 (PD-L1) expression (14). Here, CD8A is linked to neoplasm.